SCHEMBL249643

SCHEMBL249643

Oc1cccc2c1[N]CCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
TSHR P16473 3/20 0.36
NOS3 P29474 1/20 0.35
ALOX15 P16050 3/20 0.34
HSD17B10 Q99714 3/20 0.34
TDP1 Q9NUW8 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
THRB P10828 2/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HPN P05981 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX5 P09917 1/20 0.34
PTGS1 P23219 1/20 0.34
PDE4A P27815 1/20 0.34
KDR P35968 1/20 0.34
KMT2A Q03164 1/20 0.34
SIRT5 Q9NXA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL11832552 0.98 BCL2L1 (0.47) BCL2L1BADTSHRNOS3ALOX15
SCHEMBL9404818 0.88 BCL2L1 (0.42) BCL2L1BADTSHRALOX15HSD17B10
SCHEMBL5539619 0.76 NOS3 (0.37) BCL2L1BADTSHRNOS3L3MBTL1
SCHEMBL8860490 0.76 NOS3 (0.43) BCL2L1BADTSHRNOS3HSD17B10
SCHEMBL5545432 0.76 TSHR (0.36) BCL2L1BADTSHRNOS3MEN1
SCHEMBL5544284 0.76 NOS3 (0.39) BCL2L1BADTSHRNOS3
SCHEMBL1091403 0.76 ALOX12 (0.38) BCL2L1BADTSHRNOS3HSD17B10
SCHEMBL5545601 0.76 ACHE (0.41) BCL2L1BADTSHRNOS3CYP1A2
SCHEMBL13313105 0.72 BCL2L1 (0.39) BCL2L1BADTSHRALOX15HSD17B10
SCHEMBL301029 0.72 NPC1 (0.41) DRD2DRD3CA1CA2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3506983-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME Mebias Discovery LLC (US) 2019-07-10 EP claimed
US-20190194178-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY LLC 2019-06-27 US claimed
WO-2018045229-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY LLC (US) 2018-03-08 WO claimed
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP claimed
CN-109843379-B Substituted ureas and methods of making and using the same 梅比斯发现公司 2022-12-30 CN disclosed
US-11198685-B2 Substituted ureas and methods of making and using same MEBIAS DISCOVERY, INC. (US) 2021-12-14 US disclosed
US-20200308155-A1 Substituted Ureas and Methods of Making and Using Same MEBIAS DISCOVERY, INC. 2020-10-01 US disclosed
US-10683283-B2 Substituted ureas and methods of making and using same MEBIAS DISCOVERY, INC. (US) 2020-06-16 US disclosed
EP-3506983-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME Mebias Discovery LLC (US) 2019-07-10 EP disclosed
US-20190194178-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY LLC 2019-06-27 US disclosed
WO-2018045229-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY LLC (US) 2018-03-08 WO disclosed
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 US disclosed
EP-0313081-B1 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same OTSUKA PHARMA CO LTD (JP) 1994-02-02 EP disclosed
EP-0313081-A2 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683283-B2 Substituted ureas and methods of making and using same UMPS, METTL3, UTS2R BCL2L1 3074/4885BAD 2272/4885TSHR 4797/4885
US-20190194178-A1 SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME UMPS, METTL3, UTS2R BCL2L1 3074/4885BAD 2272/4885TSHR 4797/4885
US-11198685-B2 Substituted ureas and methods of making and using same UMPS, METTL3, UTS2R BCL2L1 3074/4885BAD 2272/4885TSHR 4797/4885
US-20200308155-A1 Substituted Ureas and Methods of Making and Using Same UMPS, METTL3, UTS2R BCL2L1 3074/4885BAD 2272/4885TSHR 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.